Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1998-6-8
|
| pubmed:abstractText |
Cleavage of non-viral proteins is rarely observed with the HIV-1 protease (HIV pr). One such cleavage event occurs with bcl-2, an important cytoprotective protein. The loss of bcl-2 has biological consequences, leading to enhanced HIV replication and programmed death of the host cell. A strategy is proposed to suppress HIV with non-cleavable mutants of bcl-2.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0065-2598
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
436
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
27-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading | |
| pubmed:year |
1998
|
| pubmed:articleTitle |
A cellular anti-apoptosis protein is cleaved by the HIV-1 protease.
|
| pubmed:affiliation |
DuPont Merck Pharmaceutical Co., Experimental Station, Wilmington, Delaware 19880-0336, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|